Abstract
Animal models are important for defining paradigms of tumor immunology and for evaluating therapeutic efficacy of immunotherapy. Many animal models have been used for evaluating in vivo characteristics of malignant gliomas and their responses to therapy. No animal model, however, is perfect because malignant glioma has a very heterogeneous biological behavior. There are so many parallels between mouse and human immunology, but there are significant discrepancies in immune system. Animal models for vaccine therapy can be classified as transplantable tumor models and models of spontaneous tumor in genetically engineered animals. Although transplantable tumor models have been used to test immunotherapeutic efficacy and remain a mainstay in study of brain tumor immunology, a lot of tumor vaccines that look promising in experimental animals have turned out to be ineffective clinically. Recent advances of laboratory techniques and understanding of genetic and molecular characteristics of gliomas allows for animal models of gliomas with similar biologic characteristics. Well-designed glioma models that accurately reflect the biology, pathology and clinical behaviors of human gliomas can provide more useful preclinical informations to predict clinical efficacy of novel immunotherapies and cancer vaccines.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172:2731–2738.
Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006; 12:5288–5297.
Smilowitz HM, Weissenberger J, Weis J et al. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplatanble in vivo model for malignant glioma. J Neurosurg 2007; 106:652–659.
Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998; 36:91–102.
Fleshner M, Watkins LR, Redd JM et al. A 9L gliosarcoma transplantation model for studying adoptive immunotherapy in the brains of conscious rats. Cell Transplant 1992; 1:307–312.
Parsa AT, Chakrabarti I, Hurley PT et al. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery 2000; 47:993–1000.
Heimberger AB, Crotty LE, Archer GE et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000, 103:16–25.
Albright L, Madigan JC, Gaston MR et al. Therapy in an intracerebral murine glioma model, using Bacillus Calmette-Guerin, neuramindase-treated tumor cells and 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res 1975; 35:658–665.
Finkelstein SD, Black P, Nowak TP et al. Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. Neurosurgery 1994; 34:136–143.
Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004; 16:143–150.
Hann B, Balmain A. Building “validated” mouse models of human cancer. Curr Opin Cell Biol 2001; 13:778–784.
Smilowitz HM, Weissenberger J, Weis J et al. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplatanble in vivo model for malignant glioma. J Neurosurg 2007; 106:652–659.
Theurillat JP, Hainfellner J, Maddalena A et al. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am J Pathol 1999; 154:581–590.
Weissenberger J, Steinbach JP, Malin G et al. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 1997; 14:2005–2013.
Aguzzi A, Brandner S, Isenmann S et al. Transgenic and gene disruption techniques in the study of neurocarcinogenesis. Glia 1995; 15:348–364.
Weiss WA, Israel M, Cobbs C et al. Neuropathology of genetically engineered mice: Consensus report and recommendations from an international forum. Oncogene 2002; 21:7453–7463.
Watanabe K, Tachibana O, Sata K et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6:217–224.
Ding H, Shannon P, Lau N et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 2003; 63:1106–1113.
Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215–221.
Holland EC, Hively WP, DePinho RA et al. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998; 12:3675–3685.
Bachoo RM, Maher EA, Ligon KL et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002; 1:269–277.
Zhu Y, Guignard F, Zhao D et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005; 8:119–130.
Kwon CH, Zhao D, Chen J et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 2008; 68:3286–3294.
Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29–39.
Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64:6892–6899.
Fraser MM, Zhu X, Kwon CH et al. Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 2004; 64:7773–7779.
Wei Q, Clarke L, Scheidenhelm DK et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 2006; 66:7429–7437.
Holland EC, Celestino J, Dai C et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000; 25:55–57.
Uhrbom L, Dai C, Celestino JC et al. Ink4-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 2002; 62:2065–2069.
Ding H, Shannon P, Lau N et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 2003; 63:1106–1113.
Ding H, Roncari L, Shannon P et al. Astrocyte-specific expression of activated p21-ras results in malingnant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001; 61:3826–3836.
Shannon P, Sabha N, Lau N et al. Pathological and molecular progression of astrocytomas in a GFAP: 12 V-Ha-Ras mouse astrocytoma model. Am J Pathol 2005; 167:859–869.
Weiss WA, Burns MJ, Hackett C et al. Genetic determinants of malignancy in a mouse for oligodendroglioma. Cancer Res 2003; 63:1589–1595.
Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 1998; 95:1218–1223.
Uhrbom I, Hesselager G, Nister M et al. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 1998; 58:5275–5279.
Assanah M, Lochhead R, Ogden A et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 2006; 26:781–790.
Marumoto T, Tashiro A, Friedmann-Morvinski D et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009; 15:110–116.
Abdallah B, Hassan A, Benoist C et al. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther 1996; 7:1947–1954.
Hirko AC, Buethe DD, Meyer EM et al. Plasmid delivery in the rat brain. Biosci Rep 2002; 22:297–308.
Wiesner SM, Decker SA, Larson JD et al. De novo induction of genetically engineered brain tumors in mice using plasmd DNA. Cancer Res 2009; 69:431–439.
Charest A, Wilker EW, McLaughlin ME et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycine signaling axis to form glioblastoma in mice. Cancer Res 2006; 66:7473–7481.
Koutcher JA, Hu X, Xu S et al. MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia 2002; 4:480–485.
Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requiredments using bioluminescence imaing of cell proliferation in a mouse glioma model. Nat Med 2004; 10:1257–1260.
Pittet MJ, Valmori D, Dunbar PR et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T-cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190:705–715.
Gnjatic S, Nagata Y, Jager E et al. Strategy for monitoring T-cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 2000; 97:10917–10922.
Harris JE, Ryan L, Hoover Jr HC et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18:148–157.
Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996; 156:2918–2926.
Ardavin C, Amigorena S, Reis e Sousa C. Dendritic cells: immunobiology and cancer immunotherapy. Immunity 2004; 20:17–23.
Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991–998.
Bauer C, Bauernfeind F, Sterzik A et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 2007; 56:1275–1282.
Park SD, Kim CH, Kim CK et al. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 2007; 25:3485–3491.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Chung, DS., Kim, CH., Hong, YK. (2012). Animal Models for Vaccine Therapy. In: Yamanaka, R. (eds) Glioma. Advances in Experimental Medicine and Biology, vol 746. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3146-6_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3146-6_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3145-9
Online ISBN: 978-1-4614-3146-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)